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Abstract: Secreted extracellular vesicles (EVs) are heterogeneous cell-derived membranous granules
which carry a large diversity of molecules and participate in intercellular communication by transfer-
ring these molecules to target cells by endocytosis. In the last decade, EVs’ role in several pathological
conditions, from etiology to disease progression or therapy evasion, has been consolidated, including
in central nervous system (CNS)-related disorders. For this review, we performed a systematic search
of original works published, reporting the presence of molecular components expressed in the CNS
via EVs, which have been purified from plasma, serum or cerebrospinal fluid. Our aim is to provide
a list of molecular EV components that have been identified from both nonpathological conditions
and the most common CNS-related disorders. We discuss the methods used to isolate and enrich
EVs from specific CNS-cells and the relevance of its components in each disease context.
Keywords: extracellular vesicles; central nervous system; biomarkers
1. Introduction
Extracellular vesicles (EVs) are cell-derived, membrane-bound structures, secreted
into the extracellular environment by most, if not all, cell types. There is mounting evidence
that EVs take part in control of normal physiological processes, in homeostasis control and
in cell-to-cell communication within tissues and organs. Based on development of the EV
field, different types of vesicles have been described, and include apoptotic bodies which
range in size from 50 to 5000 nm, microvesicles (50–1000 nm), exosomes (40–200 nm) and
the more recently recognized exomeres [1–4].
The EVs have started to attract attention also as potential disease biomarkers and as
new ways to study the control of cell biology. They seem to offer diagnostic capacity of
organ dysfunctions via the body fluids as the components of the “liquid biopsy” type of
sample. For example, solid tumors exhibit the elusive nature of transformed cells. They
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grow into organs but can metastasize to distant locations. The original tumor cells and
their metastases secrete EVs and this has offered a promising way to diagnose cancers from
its inception [5]. By studying the detailed molecular content of the cancer cell secreted
EVs, tumor specific signatures may be defined and information about the changes in the
associated biological processes gained.
In central nervous system (CNS) diseases, such as Alzheimer’s disease, Parkinson’s
disease, multiple sclerosis, amyotrophic lateral sclerosis, gliomas, traumatic brain injury,
stroke, schizophrenia and major depressive disorders, neuroscientists and neurologists
cannot easily access the diseased tissues for diagnostic purposes. If brain biopsy is to be
taken, it might not be representative of the common neurological disorder. Therefore, if the
EVs that would be released from the CNS to systemic circulation could be identified reliably,
this would provide a breakthrough to advance diagnostics of neurological diseases [6].
One of the challenges when working with EVs, particularly for CNS and CNS-related
pathological conditions, is to ensure that the CNS-derived EVs can be isolated from the
biological fluids (e.g., plasma (containing blood clotting agents), serum (without blood
clotting agents) or cerebrospinal fluid (CSF)) and that these indeed would have originated
from neural cells. Since EVs also contain the HLA-associated, self-depicting peptides and
wealth of other types of cargo proteins of donor cells, such EV molecules may serve to
identify specific organ level signatures, thus portraying the cell of origin. Since the EVs
also have the ability to cross the blood–brain barrier (BBB) this raises the possibility that
EV molecular content in biological fluids may reflect certain neuronal processes, as well [7].
Currently a relatively large body of literature documents the importance of EVs, but none
has yet systematically summarized EVs molecular content in association with CNS and
common CNS-related diseases. In this review, we provide a catalogue of CNS-derived EVs’
molecular cargo, both in nonpathological and selected pathological conditions.
2. Methods
A PubMed search was conducted, with the query (extracellular vesicles OR exosomes
OR microvesicles) AND (markers OR biomarkers) AND (brain OR central nervous system),
with no time interval restraints. Only original studies written in English were considered.
The retrieved records from the search were collected into the reference manager Endnote.
All abstracts were critically assessed to select only those providing meaningful information
related to the topic. Only studies using human cerebrospinal fluid (CSF), serum or plasma
samples were included. A flow diagram with a summary of the methodology is provided
in Figure 1.
Int. J. Mol. Sci. 2021, 22, 3267 3 of 32Int. J. Mol. Sci. 2021, 22, x FOR PEER REVIEW 3 of 33 
 
 
Figure 1. Flow diagram representing a summary of the conducted methodology for this review. 
3. Methods and Factors for Isolation of Central Nervous System Extracellular Vesicles 
in Liquid Biopsies 
Currently, as EVs are known to be able to cross the BBB, they are considered as po-
tential biomarkers for monitoring CNS disorders as well as specific treatment responses. 
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may be taken further by using cell-specific protein markers to enrich for EVs of specific 
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ious types of neurons, astrocytes, oligodendrocytes, microglia and Schwann cells, and en-
dothelial cells. EVs carry a variety of molecules related to neuronal function and neuro-
transmission in the brain. This contributes to the communication between nerve cells (for 
example, neuron–glia interaction), synaptic plasticity, and neuron development. Interest-
ingly, Fiandaca et al. developed an immunoprecipitation-based method to isolate EVs rich 
in neuron sources from blood. This technology has been also used by others and consists 
of two steps: a preliminary separation of total EVs from plasma or serum samples using 
commercially available polymers for high-throughput particle precipitation, and im-
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Currently, as EVs are known to be able to cross the BBB, they are considered as
potential biomarkers for monitoring CNS disorders as well as specific treatment responses.
Of particular interest is the ability to characterize EVs based on their source, which may
provide insight into the target disease. Although the majority of EVs research is performed
through cell culture, the number of reports aiming at identifying biological fluids’ EVs
originated in different cell types is rising. Multiple methods (including ultracentrifugation,
immunomagnetic beads, and size exclusion chromatography) can be used to separate
mixed EVs (from multiple cell types) from different biological fluids [8]. This step may be
taken further by using cell-specific protein markers to enrich for EVs of specific cell types
from a mixed population of vesicles.
Specifically, EVs from the CNS are secreted from almost all cell types, including
various types of neurons, astrocytes, oligodendrocytes, microglia and Schwann cells,
and endothelial cells. EVs carry a variety of molecules related to neuronal function and
neurotransmission in the brain. This contributes to the communication between nerve
cells (for example, neuron–glia interaction), synaptic plasticity, and neuron development.
Interestingly, Fiandaca et al. developed an immunoprecipitation-based method to isolate
EVs rich in neuron sources from blood. This technology has been also used by others
and consists of two steps: a preliminary separation of total EVs from plasma or serum
samples using commercially available polymers for high-throughput particle precipitation,
and immunoprecipitation with biotinylated antibodies against the neuron surface marker
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neuronal markers L1 cell adhesion molecule (L1CAM, CD171) [9]. Furthermore, L1CAM
and the GluR2/3 subunits of glutamate receptors have been used for the identification
of EVs that may be released from developing and mature hippocampal neurons [10,11].
Hence, using this method, EVs of neuronal origin may be enriched and evaluated based on
proteins, lipids and nucleic acids.
Although neuron-derived EVs are a common target in several studies, researchers are
also interested in isolating EVs originating from other CNS cells, aiming also to translate
via the EVs the origin of CNS-related diseases. The above-mentioned methodology can also
be used to enrich for EVs from other cellular origins with antibodies against specific cell
surface components. For example, for astrocytic-derived EVs enrichment, glial fibrillary
acidic protein (GFAP), glutamine aspartate transporter (GLAST), and glutamine synthetase
(GLUL) have been suggested to be specific enough to obtain CNS related EVs [12]. Ad-
ditionally, for EVs originated in oligodendrocytes, myelin proteolipid protein (PLP) and
2′,3′-cyclic nucleotide 3′-phosphodiesterase (CNP) have been proposed as specific enough
to identify the cell from which the EVs derived [13] (Figure 2).
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Figure 2. Schematic representation of the brain microenvironment, its main cellular components and how the brain–blood-
barrier permeability allows for extracellular vesicles to reach circulation. Created with BioRender.com.
The application of specific immunoaffinity-based methodology for the isolation of
CNS-related EVs in biological fluids, applied to different CNS diseases research, has led to
promising results [9,14]. Once the enriched fraction of EVs is obtained, either surface or
cargo content can be analyzed using different approaches according to the molecular target
of interest, such as proteomics (e.g., mass spectrometry, Western blot or enzyme-linked
immunosorbent assays) and/or transcriptomics methodologies (e.g., high-throughput
RNA sequencing or RT-qPCR). This opens a new avenue for research, using CNS-derived
EVs as vehicles for disease monitoring.
4. Central Nervous System Disease-Related Biomarkers in Extracellular Vesicles
CNS-related disorders, including neurodegenerative diseases, such as Alzheimer’s
(AD) and Parkinson’s (PD) diseases, malignant tumors, such as gliomas, and psychiatric
disorders, are very different pathological conditions, but share common features: anatomi-
cal origin and difficult early diagnosis. The existing liquid biopsies and imaging biomarkers
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are rather imperfect, because their dynamic range does not cover the entire course of the
disease, and their classification accuracy is lower than the level accepted for clinical prac-
tice, thus, precluding their routine implementation. Thus, the use of CNS-enriched EVs
and their molecular content as biomarkers for these specific pathological conditions may
revolutionize the clinical management of these patients. Indeed, a growing number of
studies within this field have been published in the last few years. To simplify, a summary
of the main publications retrieved from the database query can be found in Tables 1 and 2,
referring to either cargo or surface molecules, respectively [9,12,15–97] (Figure 3).
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Figure 3. Schematic representation of the use of extracellular vesicles in liquid biopsies for identification of specific central
nervous system (CNS)-related pathological conditions. Created with BioRender.com (accessed on 20 March 2021).
Alzheimer’s disease (AD) is neurodegenerative disorder characterized by memory
loss and behavioral changes. EVs have been studied as a potential diagnostic marker for
AD. This isease as a complex progression including early development of neuronal dys-
plasi , angio enic changes, release of inflammatory mediators by CNS glial and peripheral
immune cells, and developm nt f extracellular myloid-β (Aβ) fibrils that deposit in the
brain as amyloid plaques, and impair synaptic plasticity [98]. A the molecular level, the
xtracellular deposition of insoluble amyloid-β Aβ peptide plaques (39–43 amino acids
produced by amyloi precursor prot in, APP, peptides) occurs, which can intera t with
regulatory p oteins to phosphorylate the microtubule-associated protein tau. The increase
of phosphorylated tau p otein (P-S396-tau, P-T181-tau) and Aβ42 detected in plasma EVs
is associated with in reased risk for AD [98]. Of note, both Aβ and tau are secreted by
neurons through the release of EVs [12,26,36,56,90]. Moreover, some authors also studied
m lecules found in EVs from patients suffer ng from mild cognitive impairm nt. Their
memory has deficits that o not significantly affect d ily functioning, but are often regarded
and tr ate as early phase AD [52,55,99].
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Table 1. Extracellular vesicles protein and protein-coding genes transcripts as biomarkers associated with central nervous system pathological conditions.










Markers of brain insulin resistance in







Patients (N = 28),
HC (N = 28);
L.S.:






10♂(69 & 78 yrs)
Thromboplastin-D +
3000× g (30′ at 4 ◦C) +
ExoQuick®
+ L1CAM IP
Reduction of the marker levels in NDEVs
may be indicative of the extent of cognitive




AD patients (N = 20),
MCI patients (N = 10),




Thrombin + 6000× g (20′
at 4 ◦C) + ExoQuick®
+ L1CAM IP
Tau was found free-floating with a small
component inside EVs; full-length Tau was
higher inside EVs than in free solution.
[36]
SNAP-25 AD Serum AD patients (N = 24),HC (N = 17)
AD—16♀+ 8♂(78 yrs)
HC—13♀+ 4♂(77 yrs)
10,000× g (10′ at RT) +
ExoQuick®
+ L1CAM IP
The levels of SNAP-25 carried by NDEVs




N-224 tau AD Serum
Patients w/CSF+
biomarkers (N = 4), patients
w/CSF- biomarkers (N = 4)
n.m.
4000× g (20′ at 4 ◦C) +
ExoQuick®
+ L1CAM IP
N-224 tau was present in NDEVs, while
N-123 tau showed comparable
concentrations in both NDEVs and
peripherally derived EVs.
[56]





Thrombin + 14,000× g (5′
at 4 ◦C) + 3000× g (15′ at
4 ◦C) + ExoQuick®
EVs BACE1-AS transcript levels in AD
patients were significantly higher compared
with the HC (sensitivity 87.5%,
specificity 61.3%)
[96]
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AD patients (N = 12),
FTD patients (N = 16), HC
(N = 28);
L.S.:
AD patients (N = 9), FTD
patients (N = 10),








3000× g (30′ at 4 ◦C) +
ExoQuick®
+ L1CAM IP
SYP, SYNPO, SYT2, and NRGN levels were
significantly lower in patients with FTD
and AD than in HC. Some markers were
decreased years before dementia in FTD
and AD patients.
[22]
Tau AD andPD Plasma
AD patients (N = 106),
PD patients (N = 91),




2000× g (15′) +
ultracentrifugation +
L1CAM IP
Tau was significantly higher in PD patients






LRRK2+ mutation (N = 19),
LRRK2− (N = 19);
HC:
LRRK2+ (N = 39),









10,000× g (30′ at 4 ◦C) +
ultracentrifugation
pS1292-LRRK2 levels in CSF EVs were near
saturated in most subjects, 10-fold higher
than in urinary EVs, irrespective of LRRK2





PD Serum PD patients (N = 60) 17♀+ 43♂(60 yrs)
4500× g (20′ at 4 ◦C) +
ExoQuick®
+ L1CAM IP
Exenatide-treated patients had elevated
expression of tyrosine phosphorylation of
IRS-1 and of downstream targets, total Akt
and p-mTOR.
[54]
α-synuclein PD Plasma PD patients (N = 267), HC(N = 215)
PD—119♀+ 145♂(66 yrs)
HC—99♀+ 116♂(66 yrs)
2000× g (15′) +
ultracentrifugation +
L1CAM IP
Levels of α-synuclein in EVs were
substantially higher in PD patients than in
HC. A significant correlation between
α-synuclein found on EVs and disease
severity was observed.
[18]
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Table 1. Cont.
Molecule Disease Sample Type Sample Grouping and Size Patients Gender andMean Age EVs Isolation Method Key Findings Ref.
α-synuclein PD Serum
PD patients:
Tremor type (N = 22),
Non-tremor (N = 16);
essential tremor (ET)
patients (N = 21);







3000× g for (15′ at 4 ◦C)
+ ExoQuick®
+ L1CAM IP
α-synuclein levels were lower in the PD
group than in the ET and HC. Levels were
lower in the NTD group than in the TD
group. α-synuclein was found to
moderately aid in PD diagnosis
(AUC = 0.675) and had a potential to















2000× g (15′) +
ultracentrifugation +
L1CAM IP
α-synuclein levels in NDEVs were
significantly higher in patients with
early-stage PD compared with HCs.
Longitudinally increased α-synuclein were
associated with higher risk for motor








MCI Plasma MCI patients (N = 61),HC (N = 76)
MCI—39♀+ 22♂(70 yrs)
HC—47♀+ 29♂(68 yrs)




NDEVs concentrations of Aβ1-42 were
significantly increased while NRGN,
synaptophysin, synaptotagmin, and
synaptopodin levels were significantly











MCI patients (N = 21),
AD patients (N = 27),
PD patients (N = 28),
young HC (N = 15),
middle-aged HC (N = 21),











ApoE and Aß-42-positive particle
concentrations were reduced in middle and
older age subjects, whereas apoAI
increased with age. ApoAI and annexin V
levels were reduced in MCI and/or AD
patients vs. HCs.
[21]
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Table 1. Cont.
Molecule Disease Sample Type Sample Grouping and Size Patients Gender andMean Age EVs Isolation Method Key Findings Ref.
GSN,
BCHE DLB Plasma
DLB patients (N = 19),
AD patients (N = 10),







2500× g (15′) + 16,000×
g (10′) + SEC
Gelsolin decreased levels were found on
EVs from DLB patients, compared to HCs








MCI patients (N = 20),
AD patients (N = 10),
MCI-to-AD (ADC) patients
(N = 20)







Abnormal NDEVs levels of P-tau, Aß1-42,
NRGN and REST accurately predicted








MCI patients (N = 12),
mild AD patients (N = 12),
moderate AD patients
(N = 12),
severe AD patients (N = 20),









2000× g (20′) + 10,000×
g (20′) + Total Exosome
Isolation reagent
(InvitrogenTM)
Abnormal APP levels and pTau-T181/tTau
ratio in EVs demonstrated a high accuracy




MS patients (N = 10),
NMOSD patients (N = 10),
idiopathic longitudinally
extensive transverse myelitis




18,000× g (30′) +
ultracentrifugation
442 significant proteins generated a list of
signature molecules of diseases validated
primarily by the identification of known











Plasma kallikrein and Apolipoprotein-E4
were increased in CSF-EVs compared to
CSF.
[31]
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Molecule Disease Sample Type Sample Grouping and Size Patients Gender andMean Age EVs Isolation Method Key Findings Ref.
MOG MS Serum andCSF
RRMS patients (N = 45),
secondary progressive MS
(SPMS) patients (N = 30),
HC (N = 45)
n.m. ExoQuick®
Exosomal content of MOG strongly
correlated with disease activity and was

















A high number of acid
sphingomyelinase-enriched EVs correlated







ALS Plasma ALS patients (N = 30)HC (N = 30)
ALS—15♀+ 15♂(71 yrs)
HC – n.m.
1600× g (20′) +
ultracentrifugation
Microvesicles (MVs) and Exosomes (EXOs)
size were increased in ALS patients
compared to HCs; MVs of ALS patients
were enriched with toxic proteins
compared to HCs.
[48]
CUEDC2 ALS CSF ALS patients (N = 4),HC (N = 4)
ALS—4♂(58 yrs)
HC—4♂(59 yrs)
2000× g (5′ at 4 ◦C) +




By RNA sequencing, several genes, such as
CUEDC2, in CSF EVs were suggested to be







patients (N = 994) 210
♀+ 784♂(59 yrs) 3000× g (15
′) +
ExoQuick®
EV proteins cystatin C and CD14 were
related to CWMLs and the progression of
brain atrophy in patients with manifest
vascular disease.
[16]
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Acute mild TBI (N = 18),
chronic mild TBI (N = 14),







3000× g (30′ at 4 ◦C) +
ExoQuick®
+ L1CAM IP
Increases in NDEV levels of most
neurofunctional proteins in acute mild TBI,
and elevations of most NDEV
neuropathological proteins in chronic and









500× g (10′ at 4 ◦C) +
2000× g (30′ at 4 ◦C) +
ultracentrifugation
CSF after severe TBI contains Flotillin+ EVs.
Unfavorable outcomes included decreasing





Mild TBI patients (N = 19),
HC (N = 20)
Mild TBI—19♂(22 yrs)
HC—20♂(22 yrs)
Thrombin + 10,000 rpm
(5′) +
ExoQuick® + L1CAM or
GLAST IP
NDEV and ADEV levels of Aβ42 were
significantly higher while NDEV and
ADEV levels of neurogranin were









W/CI (N = 26),
W/o CI (N = 21);
Controls:
W/CI (N = 19),









3000× g (30′ at 4 ◦C) +
ExoQuick®
+ L1CAM IP
Aβ42 and P-tau species, and their
respective putative receptors, PrPc and
synaptogyrin-3, remain elevated for
decades after TBI, and may mediate
TBI-associated CI.
[81]
Int. J. Mol. Sci. 2021, 22, 3267 12 of 32
Table 1. Cont.





sTBI patients (N = 24);
mtTBI patients:
Early (N = 10) and
late (N = 15);
sTBI controls (N = 12);
mtTBI controls:
Early (N = 5) and













3000× g (30′ at 4 ◦C) +
ExoQuick®
+ GLAST IP
TBI increased plasma ADEVs levels of
neurotoxic complement proteins. [82]
NfL TBI Plasma
1–2 TBIs patients (N = 94),
≥3 TBIs patients (N = 56),






Thrombin + 10,000 rpm
(5–10′) + ExoQuick®
Repetitive mild TBIs were associated with







TBI Serum TBI patients (N = 21) 3♀+ 18♂(52 yrs) 3000× g (15
′ at 4 ◦C) +
ExoQuick®
Patients with diffuse injury displayed
higher acute EVs NFL and GFAP
concentrations than those with focal lesions.










W/CI (N = 35),
W/o CI (N = 30);
Controls:
W/CI (N = 30),










All significantly associated biomarkers
combined separated TBI w/vs. w/o CI
(AUC = 0.85) and CI w/vs. w/o TBI
(AUC = 0.88).
[89]
Int. J. Mol. Sci. 2021, 22, 3267 13 of 32
Table 1. Cont.





Stroke Serum Patients (N = 16),HC (N = 80)
Stroke—n.m.
HC—40♀+ 40♂(n.m.)
2000× g (30′) +
Total Exosome Isolation
reagent/
3000× g (15′) +
ExoQuick®
The AUC for ASC was 0.99, whereas the
AUC for caspase-1, IL-1β, and IL-18 were
0.75, 0.61, and 0.67, respectively, and can act









CSF Patients (N = 15),HC (N = 16)
Patients—15♂(n.m.)
HC—16♂(n.m.)
1200× g (20′ at 4 ◦C) +





T-tau and p-tau181 levels of CSF-derived
EV were positively correlated with the t-tau
and p-tau181 levels of total CSF in patients,






ME/CFS patients (N = 99),
ICF patients (N = 6),
depression patients (N = 8),
HC (N = 56)
n.m. SEC (qEV iZON Science)
Talin-1, filamin-A, and 14-3-3 family
proteins were the most abundant proteins









severe ABE patients (N = 10),






2000× g (20′ at 4 ◦C) +
Ribo™ exosome isolation
reagent
A total of 291 dysregulated proteins were
identified by comparing ABE patients with
HCs, by mass spectrometry. S100a9, S100a7,






Epilepsy patients (N = 115),
ADD patients (N = 10),





3000× g (15′ at 4 ◦C) +
ExoQuick®
α-synuclein levels were significantly
increased in children with epilepsy and
with ADD of the CNS and correlated with
measures of disease severity. IL-1β levels
showed significant correlation only with




SCZ patients (N = 2),
HC (N = 14)
SCZ—2♀(56 yrs)
HC—n.m.
2000× g (20′ at RT) +
13,000× g (2′ at RT) +
flow cytometric assay
SCZ patients displayed more
phosphatidylserine+ EVs in CSF compared
with HCs.
[15]
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Table 1. Cont.









IL-34/CD81 levels were significantly higher
in MDD group compared to HC group.
Synaptophysin (SYP), SYP/CD81, and
TNFR1/CD81 were positively correlated
with severities of depression and/or
various subsymptoms.
[39]




Thrombin + 4500× g (20′
at 4 ◦C) + ExoQuick® +
L1CAM IP
An increased concentration of IRS-1 in EVs
of MDD patients was found, as compared
with HC. Gender differences were observed








Infliximab-treated (N = 27),





Thrombin + 4500× g (20′
at 4 ◦C) + ExoQuick®
+ L1CAM IP
Higher levels of physical abuse were
associated with larger biomarker decreases
over time. The antidepressant response to
infliximab was moderated by TNFR1. In
infliximab-treated participants, reductions
in TNFR1 levels were associated with




GM patients (N = 17),
HC (N = 15) n.m.




EVs mRNA levels of MGMT and APNG
correlate well with levels found in parental
cells and change considerably during
treatment of seven GM patients.
[19]
EGFRvIII
mutation GM CSF GM patients (N = 71) 20
♀+ 51♂(61 yrs) 1500× g (10
′) +
ultracentrifugation
EGFRvIII was detected in CSF-derived EVs
for 14/23 EGFRvIII tissue+ GM patients.
Only one of the 48 EGFRvIII tissue- patients
had the EGFRvIII mutation detected in EVs.
Sensitivity and specificity of EVs to detect
an EGFRvIII-positive GBM was 61% and
98%, respectively.
[28]
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Table 1. Cont.
Molecule Disease Sample Type Sample Grouping and Size Patients Gender andMean Age EVs Isolation Method Key Findings Ref.
EGFRvIII
mutation GM Serum/plasma
GM patients (N = 13),
HC (N = 6)
GM—4♀+ 8♂(63 yrs)
HC—n.m. Microfluidic isolation
The EVHB-Chip achieved 94% tumor-EV
specificity. EVs from serum and plasma
samples from GM patients had mutant
EGFRvIII mRNA.
[44]
PD-L1 GM Serum/plasma GM patients (N = 21),HC (N = 5) n.m.
15,000× g (10′) +
ultracentrifugation
PD-L1 DNA was present in circulating EVs
from GM patients where it correlated with








GM Plasma GM patients (N = 19),HC (N = 19)
GM—6♀+ 13♂(n.m.)
HC—n.m.




Cytokines and costimulatory molecules
were readily detected but appeared globally




GM patients (N = 15),
HC (N = 8) n.m.
Dielectrophoretic (DEP)
micro-chip device
For GM diagnosis, EV-GFAP reached 93%
sensitivity, 38% specificity, and AUC of 0.65;
for EV-Tau, 67% sensitivity, 75% specificity
and AUC of 0.71 was disclosed.
[66]
PTRF Glioma Serum Glioma patients (N = 36) n.m. 10,000× g (30
′) +
ultracentrifugation
A positive correlation between tumor grade
and PTRF expression was found in both
tumor tissues and blood EVs from GM
patients. PTRF expression in exosomes
isolated from the sera of GM patients was
decreased after surgery.
[37]
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Table 1. Cont.
Molecule Disease Sample Type Sample Grouping and Size Patients Gender andMean Age EVs Isolation Method Key Findings Ref.
EGFRvIII
mutation Glioma Serum
Grade III glioma patients
(N = 23),
Grade IV glioma patients
(N = 73)
Other neurological diseases
patients (N = 15),






600× g (10′) + 2000× g
(20′) + 10,000× g (20′) +
Total Exosome Isolation
Kit
Sensitivity and specificity of EVs EGFRvIII
detection assay in serum were 81.58% and
79.31%, respectively. EGFRvIII expression






Glioma Serum Glioma patients (N = 23),HC (N = 12)
Glioma—9♀+ 14♂(52 yrs)
HC—3♀+ 9♂(59 yrs)
2000× g (15′) +
ultracentrifugation
Protein expression of EGFR in EVs can
accurately differentiate high-grade and
low-grade glioma patients, and positively
correlates with ki-67 labeling index in
tumor tissue. NLGN3 and PTTG1 mRNA
in EVs were also validated for detecting
glioma patients.
[73]
FASN Glioma Plasma Glioma patients (N = 8 + 9),HC (N = 8 + 3) n.m.
1000× g (7′) + 10,000× g
(30′) +
ultracentrifugation
FASN was elevated in CD63+ and CD81+
EVs in glioma patient samples. [92]
GFAP,
Survivin Glioma Serum
Glioma patients (N = 8),
HC (N = 3)
Glioma—3♀+ 5♂(52 yrs)
HC—n.m.
10,000× g (80′at 4 ◦C) +
ultracentrifugation
Patients with longer time to tumor
progression exhibited a decrease in
CD9+/SVN+ and CD9+/GFAP+/SVN+
EVs immediately following survivin
vaccination; whereas, those with early
tumor progression had an increase in the
same markers, despite anti-survivin
immunotherapy.
[97]
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Table 1. Cont.
Molecule Disease Sample Type Sample Grouping and Size Patients Gender andMean Age EVs Isolation Method Key Findings Ref.
PpIX Glioma Plasma Glioma patients (N = 6) 2♀+ 4♂(59 yrs) exoEasy Maxi Kit(Qiagen)
Plasma of patients with avidly fluorescent
tumors undergoing FGS contain circulating
PpIX+ EVs at levels significantly higher
than their predosing background, which


















n.m. 15,000× g (15
′) +
ultracentrifugation
EVs with double positive CD63+/CD81+
expression are enriched in cancer cell lines
and patient plasma samples.
[69]
Abbreviations: ABE—acute bilirubin encephalopathy; AD—Alzheimer’s disease; ADD—acquired demyelinating disorders; ADEV—astrocyte-derived extracellular vesicles; ALS—amyotrophic lateral sclerosis;
CI—cognitive Impairment; CSF—cerebrospinal fluid; CWML—cerebral white matter lesion; DLB—dementia with Lewy bodies; EV—extracellular vesicles; FTD—frontotemporal dementia; GM—glioblastoma
multiforme; HC—healthy controls; ICF—idiopathic chronic fatigue; MCI—mild cognitive impairment; MDD—major depressive disorder; ME/CFS—myalgic encephalomyelitis/chronic fatigue syndrome;
miR—microRNA; MS—multiple sclerosis; mtTBI—military veterans traumatic brain injury; NDEV—neuron-derived extracellular vesicles; n.m.—not mentioned; NMOSD—neuromyelitis optica spectrum
disorders; PD—Parkinson’s disease; RRMS—relapsing-remitting multiple sclerosis; SCZ—schizophrenia; SEC—size exclusion chromatography; sTBI—sports-related traumatic brain injury; TBI—traumatic brain
injury; yrs—years.
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Table 2. Extracellular vesicles non-coding RNAs as biomarkers associated with central nervous system pathological conditions.







Patients (N = 17),
Late-onset AD (LOAD)
Patients (N = 13)




3000× g (5′) +
miRCURYTM Exosome
Isolation Kit (Exiqon)
MiR-16-5p, miR-125b-5p, miR-451a, and
miR-605-5p were differentially expressed in
the EVs of YOAD patients when compared
with HC. In LOAD patients, miR-125b-5p,
miR-451a, and miR-605-5p were similarly
altered in expression, but miR-16-5p









AD patients (N = 42),
MCI patients (N = 17),
psychiatric and neurological
controls (N = 82)
n.m.
3500× g (10′ at 4 ◦C) +
2X 4500× g (10′ at 4 ◦C) +
10,000× g (30′ at 4 ◦C) +
ultracentrifugation
A combined signature consisting of three
miRNAs and three piRNAs were suitable to
detect AD with an AUC of 0.83. The piRNA
signature could predict the conversion of
MCI patients to AD with an AUC of 0.86.
When combining the smallRNA signature












3000× g (15′) +




MiR-23a-3p, miR-223- 3p and miR-190a-5p
levels in NDEVs from AD patients were
significantly upregulated as compared with






GRN, C9orf72 and MAPT




FTD patients (N = 11),
PPA patients (N = 6),
AD patients (N = 13),









10,000× g (5′) +
miRCURYTM Exosome
Isolation Kit
In the GeNFI cohort, miR-204-5p and
miR-632 were significantly decreased in
symptomatic compared with
presymptomatic mutation carriers, with an
AUC of 0.89 and 0.81, respectively,
and 0.93 when combined. In sporadic FTD,
only miR-632 was significantly decreased
compared with AD and HC (AUC = 0.90).
[47]
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Table 2. Cont.
Molecule Disease Sample Type Sample Grouping and Size Patients Gender andMean Age EVs Isolation Method Key Findings Ref.
miR-233 Dementia Serum
Dementia patients:
First clinic visit AD (ADfirst)
(N = 11),
Treatment-receiving AD
(ADcare) (N = 11),
VD (N = 10);





3000× g (15′ at 4 ◦C) +
ExoQuick®
The median levels of EVs miR-223 was
significantly decreased in dementia







AD patients (N = 16),
AD-MCI patients (N = 16),
HC (N = 31)
n.m.
Thrombin + 6000× g (20′
at 4 ◦C) + ExoQuick® +
L1CAM IP
Measurement of miR-132-3p in NDEVs
showed good sensitivity and specificity to
diagnose AD, but did not effectively
separate individuals with AD-MCI from
HC. MiR-212 was also decreased in NDEVs












AD patients (N = 5),
PD patients (N = 7),









8000× g (5′) +
ExoQuick®
Compared to the HC, eight miRNAs were
found to be significantly elevated/declined
in AD and PD samples, of which fiour













MS Serum RRMS patients (N = 29) 17♀+ 12♂(34 yrs) SEC (qEV iZON Science)
Several combinations of two or three
miRNAs were able to distinguish active
from quiescent disease with greater than
90% accuracy. Additional miRNAs
associated with stable remission, and a
positive response to fingolimod in patients
with active disease prior to treatment.
[79]
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ALS Plasma ALS patients (N = 14),HC (N = 8)
ALS—8♀+ 6♂(62 yrs)
HC—n.m. Vn96 peptide method
MiRNAs with relevance to ALS were found
to be deregulated, including miR-9-5p,
miR-183-5p, miR-338-3p and miR-1246.
MiR-15a-5p and miR-193a-5p were
identified for their di- agnostic potential of












ALS/MND patients (N = 10
+ 10),
HC (N = 10 + 10)
n.m. Thrombin + ExoQuick
® +
L1CAM IP
Five upregulated and three downregulated
miRNA sequences significantly
distinguished ALS/MND patients from HC










A panel of four miRNAs significantly





1-2 TBIs patients (N = 73),
rTBI patients (N = 45),
HC (N = 35)





3000 rpm (5′) +
exoRNeasy
Serum/Plasma Kit
MiR-139-5p and miR-18a-5p, were
significantly differentially expressed in the
rTBI and 1-2 TBI groups. TBI history and
neurobehavioral symptom survey scores





AIS patients (N = 65),





21,000× g (15′ at 4 ◦C) +
ExoQuick®
miR-9 and miR-124 were significantly
higher in AIS patients vs. HC (AUCs of
0.8026 and 0.6976, respectively).
[23]
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Molecule Disease Sample Type Sample Grouping and Size Patients Gender andMean Age EVs Isolation Method Key Findings Ref.
miR-21-5p,
miR-30a-5p IS Plasma
HIS patients (N = 15),
AIS patients days 1-3
(N = 33),
AIS patients days 3-7
(N = 32),
SIS patients (N = 31),
RIS patients (N = 32)









16,000× g (10′ at 4 ◦C) +
exoRNeasy
Serum/Plasma Kit
MiR- 21-5p and miRNA-30a-5p in
combination are promising biomarkers for
diagnosing IS and distinguishing among
HIS, SIS, and RIS, especially miRNA-30a-5p





patients (N = 16),
NMOSD in remission
patients (N = 15),










MiR-122-3p and miR-200a-5p could
distinguish NMOSD status, and were
significantly upregulated in the serum EVs
of relapsing NMOSD compared with that in
remitting NMOSD. The two miRNAs had













2000× g (20′) + 10,000×
g (20′) + ExoQuick®
Among six candidate microRNAs,
miR-8071 had the best diagnostic value for
mTLE-HS with 83.33% sensitivity and




















SEC (qEV iZON Science)
MiR-206 was the most upregulated miRNA
in the EVs of SCZ patients. A signature of
11 miRNAs were identified in EVs from
SCZ patients and were used to classify
samples from SCZ and HC subjects with
high accuracy.
[58]
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Molecule Disease Sample Type Sample Grouping and Size Patients Gender andMean Age EVs Isolation Method Key Findings Ref.
miR-203a-3p PTSD Plasma
Discovery set:
PTSD patients (N = 12),
HC (N = 12);
validation set:
PTSD patients (N = 10),







10,000× g (10′) + SEC
(iZON Science)
The concentration changes of miR-203a-3p
in EV and miR-339-5p in EV-depleted
plasma were confirmed two independent







GM patients (N = 25),
HC (N = 25);
validation set:
GM patients (N = 50),












The expression levels of the sncRNA
RNU6-1, miR-320 and miR-574-3p were
significantly associated with a GM
diagnosis. RNU6-1 was consistently an












Discovery cohort 1 patients
(N = 24) and HC (N = 15);
discovery cohort 2 patients
(N = 40) and HC (N = 27);
discovery cohort 3 patients
(N = 13) and HC (N = 19);
validation cohort 4 patients
(N = 10) and HC (N = 12);
validation cohort 5 patients











2000× g (20′) +
ultracentrifugation
Comparison of miRNA profiles between
GM patients and HC yielded a tumor
“signature” consisting of nine miRNAs,
which correlated with GM tumor volume.
[27]




HOTAIR was present in whole serum and
purified EVs but not in serum supernatant
depleted of EVs, in GM patients.
[49]
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Molecule Disease Sample Type Sample Grouping and Size Patients Gender andMean Age EVs Isolation Method Key Findings Ref.
RNU6-1 GM Serum
GM patients (N = 18),
subacute stroke patients
(N = 30), acute/subacute
hemorrhage patients
(N = 30),
MS patients (N = 18),
brain metastases patients
(N = 21), PCNSL patients
(N = 12),












RNU6-1 expression was significantly higher
in GM patients vs. HC, and also when
comparing with patients with
non-neoplastic lesions. No significant
differences were found between GM
patients and brain metastases.
[91]





2000× g (30′) + 12,000×
g (25′) +
ultracentrifugation
MiR-21 levels in CSF-EVs of glioma patients
were found significantly higher than in
non-glioma controls; whereas no difference
was detected in serum-derived EVs. The
CSF-EVs miR-21 levels correlated with
tumor spinal/ventricle metastasis and the












3 × 3500 rpm (20′) +
ExoQuick®
Six overexpressed miRNAs were found on
EVs from glioma patients vs. HC. MiR-549a
and miR-502-5p expression predicted
prognosis in glioma patients.
[33]
miR-301a Glioma Serum Glioma patients (N = 60),HC (N = 43)
Glioma—33♀+ 27♂(n.m.)
HC—n.m.
3000× g (15′ at 4 ◦C) +
ExoQuick®
MiR-301a levels on EVs were upregulated
in glioma patients compared to HC, and
correlated with ascending pathological
grades. MiR-301a levels were significantly
reduced after surgical resection of primary
tumors and increased again during GM
recurrence, and were independently
associated with overall survival.
[40]
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Glioma patients (N = 100),
brain non-glial metastases
patients (N = 11),






3000× g (15′) +
ExoQuick®
The expression levels of miR-21, miR-222
and miR-124-3p in EVs of patients with
high grade gliomas were significantly
higher than those of low grade gliomas and
HC, and were decreased in samples
obtained after surgery.
[46]




downregulated in tumor tissues, while it
was upregulated in EVs from the same
patients with glioma, corresponding to an
AUC of 0.8663. MiR-454-3p expression was
lower in the post-operative samples. High
miR- 454-3p expression in EVs or low







GM patients (N = 25), LGA







MiR-210 was upregulated in GM and LGA,
whereas miR-185, miR-5194, and miR-449
were downregulated in GM and LGA
compared to trauma patients. MiR-5194
and miR-449 were significantly decreased
in GM patients compared with LGA.
[94]
Abbreviations: AD—Alzheimer’s disease; AIS—acute phase ischemic stroke; ALS—amyotrophic lateral sclerosis; CSF—cerebrospinal fluid; EV—extracellular vesicles; FTD—frontotemporal dementia; GM—
glioblastoma multiforme; HC—healthy controls; HIS—hyperacute phase Ischemic stroke; IS—ischemic stroke; LGA—low-grade astrocytoma; MCI—mild cognitive impairment; miR—microRNA; MND—motor
neuron disease; MS—multiple sclerosis; mTLE-HS—mesial temporal lobe epilepsy with hippocampal sclerosis; NDEV—neuron-derived extracellular vesicles; n.m.—not mentioned; NMOSD—Neuromyelitis
optica spectrum disorders; PCNSL—primary central nervous system lymphoma; PD—Parkinson’s disease; PPA—primary progressive aphasia; PTSD—post-traumatic stress disorder; RIS—recovery phase
ischemic stroke; RRMS—relapsing-remitting multiple sclerosis; rTBI—repetitive traumatic brain injury; SCZ—schizophrenia; SEC—size exclusion chromatography; SIS—subacute phase ischemic stroke;
TBI—traumatic brain injury; VD—vascular dementia; yrs—years.
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Parkinson’s disease (PD) is other common neurodegenerative disorder. Although PD
can be described more correctly as a syndrome caused by different genetic and epigenetic
alterations, a shared downstream result is the degeneration of dopamine-releasing axon
terminals in the striatum and of corresponding neurons in the substantia nigra, which leads
to impairment of motor and speech skills [100]. EVs have also been used as a diagnostic
platform for PD. Indeed, increased α-synuclein levels in plasma EVs were associated with
PD, and disease clinical severity, although results are inconsistent [18,72,88]. Moreover,
reduced levels of CSF’s EVs containing apolipoprotein A1 were associated with a higher
risk of PD [21].
Multiple sclerosis (MS) and amyotrophic lateral sclerosis (ALS) are very different
demyelinating diseases. MS is an autoimmune disease that affects the myelin sheath,
which insulates nerve cell fibers in the brain and spinal cord [101], whereas ALS is a motor
neuron disease that mainly affects the brain and spinal cord motor neuron cells [102]. For
both diseases, several efforts have been made to find disease-related biomarkers in EVs
isolated from patients’ biological fluids, with a special emphasis in non-coding RNAs.
Non-coding RNAs (ncRNAs) are also generally found in circulating EVs. There are
several ncRNA categories, commonly classified according to their size: the long ncRNAs
(lncRNAs) with more than 200 nt, and the small ncRNAs (sncRNAs), including microRNAs
(miRs), which present less than 200 nt [103,104]. These ncRNAs have been studied as
specific disease “signatures” found in EVs in various disorders including MS/ALS. In
fact, for all major group of CNS-related diseases mentioned in this review, published data
on EVs ncRNAs have been assessed. For instance, in a recent study by Ebrahimkhani
S. et al., the utility of serum exosome miRs as disease biomarkers of MS patients under
treatment with fingolimod was assessed, and they found that several combinations of
two or three miRNAs could discriminate active from quiescent disease with more than
90% accuracy [79]. Likewise, for ALS, Banack et al. found that eight miRNAs, isolated
from neural-enriched EVs, significantly distinguished ALS patients from controls, and thus
might assist in early diagnosis of this disease [75].
Gliomas are glial cell-derived brain tumors, classified according to cell type, including
ependymomas (ependymal cells), oligodendrogliomas (oligodendrocytes) and astrocy-
tomas (astrocytes). The most common and malignant primary brain tumor, the grade IV
astrocytoma/glioblastoma multiform belongs to this group of tumors [105]. Glioblastoma-
specific or glioblastoma-rich protein and genetic material can be detected in EVs isolated
from the biological fluids of glioblastoma’s patients. The usefulness of using EVs as plat-
forms for the analysis of specific biomarkers, which can help predict the disease outcome
and prognosis of GM patients, have been recently established. For example, EGFRvIII is the
oncogenic form of epidermal growth factor receptor (EGFR), never found in normal tissues.
According to various reports, EGFRvIII protein, mRNA and DNA have been detected in
plasma EVs isolated from patients with glioblastoma carrying EGFRvIII, but not in EVs
isolated from noncancer patients [28,41,44]. Similarly, multiple studies have also shown
that miR-21 levels are higher in EVs isolated from the serum and CSF of patients with
glioblastoma. This finding is supported by the higher levels of miR-21 also described in
clinical glioblastoma specimens [20,27,46].
Traumatic brain injury (TBI), also known as intracranial injury, is a brain damage
caused by external forces [106]. TBI classification can be based on severity (from mild
to severe TBI), mechanism (closed or penetrating head injury), or other characteristics
(for example, occurring in a specific location or widespread area). TBI usually causes
neurological sequels, which can be seen even in mild TBI. Mild TBI may lead to acute
symptoms, including chronic traumatic encephalopathy, cognitive impairment, dementia,
movement disorders, and motor neuron dysfunction [107]. One of the main clinical
challenges in TBI is to accurately identify its occurrence, and to determine the extent
of CNS damage. Peltz et al. showed that in war veterans with a history of TBI, CNS-
enriched exosome concentration of pTAU, NfL, IL-6, TNFa are associated with cognitive
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impairment, which may assist clinicians in choosing a more appropriate treatment schedule
and follow-up [89].
Psychiatric disorders, like schizophrenia (SCZ) or chronic depression, are estimated
to affect a major percentage of the world population and are very difficult to diagnose
and manage. Schizophrenia is a neurological disorder characterized by behavioral deficits,
associated with impaired locomotor activity and cognitive defects. The diagnosis of
schizophrenia is associated with demonstrable alterations in brain structure and changes
in dopamine and glutamate neurotransmission in the cortex [108]. In this field, there is
a demand for the discovery of biomarkers, which, if successful, can support clinicians in
personalized treatment strategies. In this context, Du Y. et al. showed that the expression
levels of specific miRs in EVs isolated from the blood of SCZ patients were sensitive to
long-term medication [58].
Stroke, which can be categorized into ischemic or hemorrhagic stroke, affects 13.7 mil-
lion people worldwide each year, and is the second leading cause of death, with 5.5 million
deaths each year [109]. A stroke occurs when the blood supply to part of the brain is
interrupted or reduced, limiting brain tissue from obtaining oxygen and nutrients, and gen-
erally causing brain damage [110]. Several authors explored the importance of the innate
immune response as a contributor to the inflammatory response after stroke [111–113]. In
this regard, Kerr et al. used a technique designated Simple Plex assay (an immunoassay in a
microfluidic cartridge) to determine the presence and concentration of some inflammasome
proteins in serum EVs of stroke patients [38]. The authors found that protein levels of
ASC (caspase-recruitment domain) remained higher in serum-derived EVs from stroke
samples, when compared to controls, and performed well as a potential biomarker for this
pathological condition [38].
Major depressive disorder (MDD) is a debilitating mental disease characterized by per-
sistent low mood. It affects the behavior as well as various physical functions, such as appetite
and sleep [114]. Although the understanding of the neurobiology of MDD has improved
in recent years, the knowledge of the mechanisms that may explain the most relevant as-
pects of the disease is limited. Nonetheless, MDD was associated with smaller hippocampal
volumes, changes in activation or connectivity of neural networks, and also changes in the
main neurobiological systems that mediate the stress response, including the hypothalamic–
pituitary–adrenal (HPA) axis, autonomic nervous system, and immune system [115,116]. The
identification of susceptibility biomarkers that might identify individuals prone to depression
and disease recurrence would improve treatment and allow for recurrence prevention. A
series of studies by different research teams have implicated a systemic metabolic dysfunction
known as insulin resistance in the pathophysiology and treatment of disorders of mood
and cognition, including MDD [117,118]. Therefore, the insulin-receptor (IR) investigated in
these studies was identified in brain areas associated with mood and cognition [119]. Indeed,
Nasca et al. recently found that insulin-receptor substrate-1 (IRS-1) was highly abundant in
neuronal-derived EVs isolated from plasma samples of MDD patients, compared to nonpatho-
logical controls, and that higher IRS-1 levels were associated with suicidality and anhedonia
in those individuals. This data could lead to an improved strategy in the treatment of MDD
patients [86].
5. Future Perspectives and Conclusions
Research based on EVs, specifically neuronal-derived EVs, is rapidly moving forward.
We have now recognized a wide range of biological processes mediated by these molecules,
and its importance into cell–cell communication, as well as disease spread within the CNS.
With increasing knowledge about EVs from specific neurological diseases and the advances
in technologies used to analyze these nanostructures, research is now moving towards
clinical translation for biomarker platforms. For this, established and validated biomarkers
are needed. Indeed, various single reports based on small cohorts have been published, but
very few were validated by larger, cross-sectional investigations. The promising results so
far point towards a future where brain-derived EVs could be used for not only for diagnosis
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of CNS-related disorders, but also for patient monitoring, and for studying the influence of
the release of this specific EVs in behavioral and mental health related conditions.
Overall, EVs produced in the brain and circulating in peripheral fluids have become
an incredible window to the brain, which is expected to assess the disease status of a
given patient with great accuracy and simplicity. In the near future, one can anticipate
that a relevant biomarker platform may move quickly into clinical context, to provide an
enormous amount of information that may assist in clinical patients’ follow-up. This may
occur at the physician’s office, as many technological solutions exist today to monitor such
biomarkers using point-of-care devices. In a long-term perspective, one may anticipate
that the information deriving from EVs may also act as an early disease warning system. It
is only natural that the biological/biochemical information of such circulating EVs shall
be better and more significant in time, considering the huge developments expected in
the fields of nanotechnology, bioengineering and artificial intelligence. Specifically, when
these are combined for the same purpose, even lower concentrations of a given pool
of biomarkers in very complex samples might be detected. Finally, it will be indeed a
breakthrough when such advanced biomarker panel from circulating EVs (that may well
derive from CNS) becomes a tool to prevent disease progression.
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